Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25

on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama:

Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an Alzheimer Disease expert from USC.

A Ray Of Hope For Medivation « The Science Business –

And John Jannarone writing in the WSJ asks if Big Pharma is too hungry for product so that small biotechs get the “upper hand” in deals.

HEARD ON THE STREET: Big Pharma Should Avoid Course in Medivation –

%d bloggers like this: